A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL
Klinische Pädiatrie · 01.05.2024 · 236 (03) · 205
DOI: 10.1055/s-0044-1786578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von C L Gehlert und 9 weiteren Autor:innen.
Abstract (Originalsprache)
A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL
Zitieren
APA
Gehlert, C. L., Schewe, D. M., Klausz, K., Schrappe, M., Cario, G., Baldus, C. D., Gramatzki, M., Lenk, L., Kellner, C., & Peipp, M. (2024). A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL. Klinische Pädiatrie, 236(03), 205. https://doi.org/10.1055/s-0044-1786578
Vancouver
Gehlert CL, Schewe DM, Klausz K, Schrappe M, Cario G, Baldus CD, et al. A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL. Klinische Pädiatrie. 2024;236(03):205. doi:10.1055/s-0044-1786578
BibTeX
@article{Gehlert2024,
author = {Gehlert, C L and Schewe, D M and Klausz, K and Schrappe, M and Cario, G and Baldus, C D and Gramatzki, M and Lenk, L and Kellner, C and Peipp, M},
title = {A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL},
journal = {Klinische Pädiatrie},
year = {2024},
volume = {236},
number = {03},
pages = {205},
doi = {10.1055/s-0044-1786578}
}
EUVIMED